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ABSTRACT 
Oral Human Papillomavirus (HPV) infection is a major cause of oropharyngeal cancer 
that is increasing in incidence over the last decades. However, little is known about the 
epidemiology of oral HPV infection. Using complex data and HPV testing results from 4724 
adults collected through National Health and Nutrition Examination Survey (2013-2014), we 
estimated the prevalence of oral HPV and evaluated risk factors associated with HPV infection. 
The oral HPV prevalence was 7.18% for any types and 4.5% for high-risk types in adults aged 
18-69 years. The prevalence varied significantly by age, demographic characteristics, and sexual 
history. Multiple factors including age, gender, and sexual history were identified as risk factors 
for oral HPV infection. Prevalence of HPV was higher in men (11.1%) than in women (3.3%). 
Several characteristics, including race, tobacco and alcohol use, and education, were identified as 
risk modifiers for HPV infection among men and women. 
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1 INTRODUCTION  
1.1 Background  
Human Papillomaviruses (HPV) are small DNA viruses with double stranded circular 
genome about ~7000-8000bp, surrounded by icosahedral capsids of 52-55nm in diameter [1, 2]. 
The genome encodes 7 early proteins (E1, E2, E4, E5A, E5B, E6, and E7) and 2 late capsid 
proteins (L1 and L2). Based on DNA sequence similarity of the late gene L1, HPVs are 
classified into α, β, and γ genera comprising more than 200 HPV types [3, 4].  
HPV infection in epithelial cells is the most common sexually transmitted disease [5]. 
HPV infection in cutaneous cells can cause warts, while in the mucosal cells HPV can cause 
genital warts and various forms of cancers including anogenital, oropharyngeal cancers, and 
possibly skin cancers [6]. It is estimated that 79 million people are infected by some types of 
HPVs in the United States [7]. While majority of HPV infection are cleared by the host immune 
system, persistent infection of HPV in a small portion of people can cause cancer [8].  About 
600, 000 incident cancers worldwide and 250, 000 premature deaths are related to HPV infection 
[9]. According to the data from National Program of Cancer Registries of Centers for Disease 
Control and Prevention (CDC), about 39,800 new cases of cancer occur annually in the human 
body sites where HPVs are frequently found in the United States. Among these cases, 79% 
(31,500) are caused by HPV infection [10]. As shown in Table 1, HPV causes 91% of cervical 
cancers and a portion of cancers on various sites including vagina (75%), vulva (69%), penis 
(63%), anus (91%), rectum (69%), and oropharynx (70%) [10]. HPV types differ in their 
potential in causing epithelial abnormalities. Most of the 200 known HPV types infect cutaneous 
epithelial cells and lead to skin wart.  More than 90% of HPV attributable cancers are caused by 
a group of HPVs (~40 types) in α genera [11].  Depending on their oncogenic potential, HPV 
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types are grouped into high-risk HPV (HRHPV) or low-risk HPV (LRHPV) [4, 12]. HRHPV 
currently include 18 types, HPV 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 69, 73, 
and 82 [13, 14]. HRHPV act as carcinogen and can result in the development of anogenital 
cancers. In cervix, HRHPV infection lead to low-grade and high-grade cervical cell 
abnormalities, which can progress to cervical cancer. HPV16 and HPV18 account for about 70% 
of all cases of cervical cancers worldwide [15, 16]. Infection with a high-risk HPV type is 
necessary, but not sufficient for the development of cervical cancer, because the vast majority of 
women with HPV infection do not develop cancer [12, 17]. LRHPV includes HPV type 6, 11, 
40, 42, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 81, subtype IS39 of HPV82, 83, 84, and 89 
[cp6108] [13, 14]. Infection with low-risk HPV types such as type 6 and 11, generally does not 
result in cancer, but can cause benign or low-grade cervical cell abnormalities, genital warts, and 
laryngeal papillomas [18].  
Human is the only natural reservoir for HPV. HPV is predominantly transmitted through 
sexual contact with an infected individual [19]. As a result, HPV infection is common among 
sexually active populations. Using data for 4150 females collected between 2003 to 2006, the 
overall prevalence of genital HPV was estimated as 42.5% in females aged 14-59 years [20]. In a 
cross-sectional study using data from National Health and Nutrition Examination Survey 
(NHANES), the overall prevalence of genital HPV was estimated as 45.2% among 1868 men 
aged 18-59 years [21]. The key risks for HPV infection are related to sexual behaviors, including 
number of sex partners, the age of sex debut, and the likelihood of sex partners being a HPV 
carrier [22, 23]. People of young age (<25 years) are vulnerable to HPV infections. A 
prospective study showed that exposure to new partners conferred high risk for incident HPV 
infections [24]. It was reported that the number of sex partners of men was a key determinant of 
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cervical cancer risk for their wives. The prevalence of penile HPV infection had a positive trend 
along with increasing number of sexual partners [25]. Additional risk factor for HPV infection 
include compromised immune system, long term use of oral contraceptives, inconsistent condom 
use, as well as smoking and alcohol use. Despite the compelling evidence that HPVs are mainly 
sexually transmitted, other transmission route, including transmission from mother to child and 
from skin to skin, were documented, although they appeared to be uncommon [19]. 
HPV vaccination for girls at age of 11 years with catch-up vaccination to age of 26 years 
was recommended by the Advisory Committee on Immunization Practice (ACIP) of the CDC in 
2006 [26]. In 2009, U.S. Food and Drug Administration (FDA) approved the use of quadrivalent 
HPV vaccine (HPV 6, 11, 16, and 18) in males with guidance from ACIP for genital wart 
prevention [27]. Routine HPV vaccination was further expanded in 2011 in male individuals 
aged 11 to 26 years [28]. Recently, a 9-valent HPV vaccine including type 6, 11, 16, 18, 31, 33, 
45, 52, and 58 was approved to prevent HPV attributable cancers and decrease HPV 
transmissions [29]. 
Oral HPVs are detected at high prevalence in oropharyngeal cancer (OPC) patients [16, 
30, 31]. Strong molecular evidence has shown that HPV plays a causal role in the development 
of OPCs, in which expression of the oncogenes (E6 and E7) and integration of HPV genomes 
have been shown [32].  HPV infection is considered to accounts for 70% of oropharyngeal 
squamous cell cancer (OPSC) in the United State (Table 1) [10]. It is estimated that about 3,200 
new cases of HPV-associated OPCs in women and about 13,200 in men occur each year in the 
United States [33]. Notably, the incidence of HPV attributable OPCs (HPV-OPC) increased by 
225% from 1988 to 2004, while the incidence of HPV negative OPCs decreased by 50% [34]. 
This data strongly suggest that HPV infection is the underlying cause for overall increase in OPC 
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incidence [34-36]. Particularly, OPC incidence among men has doubled over the past 20 years 
[37]. To date, OPC becomes the most common HPV-related cancers, its incidence among men 
(7.8 per 100,000) has surpassed incidence rates of cervical cancer among women (7.4 per 
100,000) [38]. It was reported that HPV negative OPCs were associated with chronic alcohol and 
tobacco use. In contrast, HPV positive OPCs were associated with sex behavior, particularly in 
young individuals [39]. The reason for the predominant increase of HPV positive OPCs in men 
was not clear [13]. Notably, more than 90% of HPV-positive OPCs are related to HPV16 and 
oral HPV infection confers higher risks for OPCs [39].   
Oral HPV prevalence is low compared to that of genital infections. In one study, the 
overall prevalence of oral HPV was estimated as 6.9% in people aged 14-69 years using data 
from NHANES collected from 2009 to 2010. Men had higher prevalence compared to women 
[13]. It was suggested that oral HPV infection was predominantly transmitted through sexual 
contact. Sexual behavior and current smoking, including intensity, appeared to be potentially 
modifiable risk factors for oral HPV infection. Oral HPV prevalence was elevated among people 
with more than 20 lifetime sexual partners [13]. Recently, another group examined the 
prevalence of oncogenic oral HPV using data containing participants aged 20-69 enrolled in 
NHANES from 2009 to 2014, OPC cases from Surveillance, Epidemiology, and End Results 
(SEER 18), and oropharyngeal cancer mortality from National Center for Health Statistics 
(NCHS) [40]. They found that oncogenic oral HPV DNA was detected in 3.5% of all adults aged 
20–69 years. The highest prevalence (8.1%) was observed in men aged 50–59 years old.  Factors 
conferring high risk for oncogenic oral HPV infection included number of lifetime oral sexual 
partners, tobacco use, and having  more than 5 lifetime oral sexual partners [40]. 
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Table 1  Number of HPV-associated and HPV-attributable cancer cases per year 
Cancer site 
Average 
number 
of 
cancers 
per year 
in sites 
where 
HPV is 
often 
found  
Percentage 
probably 
caused by 
any HPV 
typea 
Number 
probably 
caused 
by any 
HPV 
typea 
Percentage 
probably 
caused by 
HPV types 
16/18b 
Number 
probably 
caused 
by HPV 
types 
16/18b 
Percentage 
probably 
caused by HPV 
types 
31/33/45/52/58c 
Number 
probably 
caused by HPV 
types 
31/33/45/52/58c 
Cervix 11,693 91% 10,600 66% 7,700 15% 1,700 
Vagina 819 75% 600 55% 500 18% 100 
Vulva 3,671 69% 2,500 49% 1,800 14% 500 
Penis 1,181 63% 700 48% 600 9% 100 
Anus 5,229 91% 4,800 79% 4,200 8% 400 
Female 3,416 93% 3,200 80% 2,700 11% 400 
Male 1,813 89% 1,600 79% 1,400 4% 100 
Rectum 772 91% 700 79% 600 8% 100 
Female 528 93% 500 80% 400 11% 100 
Male 244 89% 200 79% 200 4% <100 
Oropharynx 16,479 70% 11,600 60% 9,900 6% 900 
Female 3,203 63% 2,000 51% 1,600 10% 300 
Male 13,276 72% 9,600 63% 8,400 4% 600 
TOTAL 39,844  79%  31,500  63%  25,300  10%  3,800  
Female 23,330  83%  19,400  63%  14,700  13%  3,100  
Male 16,514  73%  12,100  64%  10,600  4%  700  
 -Adopted from the CDC cancer statistics, https://www.cdc.gov/cancer/hpv/statistics/cases.htm. 
 Data are from population-based cancer registries participating in the CDC National Program of Cancer. 
Note: Registries and/or the NCI Surveillance, Epidemiology, and End Results Program, meeting criteria 
for high data quality for all years 2009 to 2013 and cover about 99% of the U.S. population. 
aHPV types detected in genotyping study; most were HRHPV types known to cause cancer.  
bHPV types 16/18 can be prevented by the bivalent, quadrivalent, and 9-valent HPV vaccines. 
cHPV types 31/33/45/52/58 can be prevented by the 9-valent HPV vaccine. 
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1.2 Significance  
With the dramatic increase of incidence of OPCs, there is an increasing interest in 
identifying healthy individuals at risk for development of oropharyngeal cancer to provide 
information for screening strategies. Due to the facts that a large portion of OPCs are caused by 
oral HPV and that HPV-related OPC has better prognosis, monitoring and understanding the 
trend of prevalence of oral HPV are essential for HPV surveillance, evaluation of the burden of 
HPV associated cancers and the efficacy of HPV vaccination, as well as cancer control and 
prevention. Despite the studies outlined above, we still have an incomplete picture regarding to 
oral HPV infection epidemiology. More data are need to confirm previous findings and provide 
update data for prevalence of oral HPV. Furthermore, analysis of risk factors for oral HPV 
prevalence and transmission holds the key for developing prevention programs. However, little is 
known about the risk factors for oral HPV infection. In this thesis, we conduct a population-
based study to investigate the prevalence of oral HPV and identify risk factors for HPV infection, 
using data collected from 2013 to 2014 through the US National Health and Nutrition 
Examination Survey (NHANES) studies. 
1.3 Data Source 
NHANES comprises a series of studies conducted by National Center for Health Statistics 
(NCHS) at the CDC [41]. It is an ongoing health and nutrition complex survey designed to assess 
the health and nutritional status of adults and children in the United States. The samples for the 
survey are selected to represent the U.S. population of all ages. NHANES uses a complex, 
multistage probability design to sample the civilian, noninstitutionalized population in the 50 
states and Washington, D.C. The survey contains HPV testing for oral and genital samples [41]. 
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The unique feature that NHANES combines interviews with physical examinations makes it a 
good choice for population-based HPV prevalence study. 
1.3.1 Survey Design 
The selection of participants involves 4 consecutive stages. Stage 1 is called primary 
sampling units (PSUs) selection. All counties are divided into 15 groups. One county is selected 
from each group, resulting in 15 counties each year. Stage 2 involves selection of segments 
within PSUs, which forms a block or group of blocks containing a cluster of households. In stage 
3, all houses or apartments in the small groups selected in stage 2 are identified, and about 30 
households are sampled from each group. In stage 4, interviewers go to each selected house and 
conduct an interview. People received interviews are invited to a Mobile Examination Center 
(MEC) for physical examination such as blood pressure, dental examination, and collection of 
specimens for laboratory testing. Some groups, such as people who are 60 years and older, 
Hispanics, Asian, and African Americans, are over sampled to produce reliable statistics [42]. 
1.3.2 Sample Weights 
Sample weights are measures of the number of persons represented by the particular 
sampled participants. Sample data weighting allows estimates that would have been obtained if 
the entire sampling frame had been surveyed. Weighting considers the different probabilities of 
selection for sampling domains, nonresponse, and difference between the final sample and total 
population. In NHANES, samples were first weighted to compensate for unequal selection 
probabilities among subgroups such as race and sex. Then samples were adjusted for 
nonresponse to reduce biases. Finally, the sample weights were post-stratified to U.S. Census 
Bureau estimates of target population totals to compensate inadequacies in the sample frame, as 
well as to reduce variance. Calculated final interview weights are used for data analysis for 
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household interview, and the final examination weights are used for examination data or in 
conjunction with house hold interview data [42].  
1.3.3 Variance Estimation 
Exact mathematical formulas for variance estimate are not available for complex sample 
survey. To provide approximately unbiased and design-consistent estimate for variance, variance 
approximation procedures are required. Because variance computations need to consider survey 
design, standard statistical software packages assuming random samples are not applicable for 
survey data. Two variance approximation procedures are used for NHAES survey analysis, 
replication methods and Taylor Series Linearization (TSL). Both methods consider the complex 
sample design and compute the design effects. The replication method was used for HNANES 
III.  Now NCHS recommends to use TSL method for variance estimation for all HNANES data. 
In this method, the linear approximation is generated by taking the first-order Taylor series 
approximation for the estimator. Then standard variance estimation methods for linear statistics 
are used to estimate the variance of the linearized estimator. Various software packages 
including SAS survey procedures, R and SUDDAN are available to estimate variance by this 
method [42]. 
1.4 Purpose of Study 
In this study, we will select variables from demographic and questionnaire survey and 
combine with oral HPV testing variables using NHANES data collected during 2013-2014. We 
will examine the data to achieve the following aims:   
Aim 1: To estimate the prevalence of oral HPV in U.S. populations aged 18-69 years  
Aim 2: To assess the distribution of HPV infection by risk categories 
Aim 3: To identify factors conferring risks for HPV infection 
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1.5    Expected Results 
We expect weighted prevalence for oral HPV infection to be between 5-10% in U.S. 
adult populations aged 18-69 years. Prevalence of different HPV types are to be estimated. 
Significant differences in distribution of HPV infection among demographic and behavioral 
characteristics are expected to be observed. A number of factors may be identified to modify the 
risk of being infected by HPV. Using multivariate logistic regression, adjusted ORs are expected 
to be generated for risk evaluation.  
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2 METHODS 
2.1 Study Population and Survey Design 
Data were extracted from NHANES website (https://wwwn.cdc.gov/nchs/nhanes 
/ContinuousNhanes/Default.aspx?BeginYear=2013). The consenting participants have household 
interviews by dietary and health interviewers followed by physical examinations in a Mobile 
Examination Center (MEC). The interview contains questions covering demographic, 
socioeconomic, dietary, and health-related topics. The examination includes medical, dental, and 
physiological measurements, as well as laboratory tests. Survey data were collected in 
consideration of diseases, health indicators and risk factors, prevalence of chronic conditions, as 
well as estimates for previously undiagnosed conditions. Like any complex survey, the data has 
the following features: unequal weights, stratification, clustering and finite population 
corrections [41]. 
NHANES 2013-2014 survey data are used for this analysis. The dataset included 14,332 
participants from 30 different survey locations. Oversampled subgroups include Hispanic 
persons, Non-Hispanic Black persons, Non-Hispanic Asian persons, Non-Hispanic White and 
other persons at or below 130 percent of the poverty level, as well as Non-Hispanic white and 
other persons aged 80 years and older. Of those participants, 10,175 (71%) completed the 
interview and 9,813 (68.5%) underwent health examinations in the MEC. We extracted data for 
5057 (51.5%) adult participants (18-69 years old) who submitted oral samples for HPV testing. 
Of these samples, 333 were inadequate for HPV DNA typing and were excluded from the 
analysis. The final dataset had 4724 participants with HPV test results [43].  
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2.2 Demographic and Behavioral Characteristics 
Demographic data, including age, gender, race, country of birth, education, and marital 
status, were obtained from the NHANES household interview survey data (2013-2014) [43]. 
Income-poverty ratio was calculated based on the U.S. Census definition by dividing total family 
income by the poverty threshold after adjusting for family size at the time of interview. 
Data on substance use, such as alcohol and tobacco, and sexual behavior were self-reported 
by participants through audio computer-assisted self-interview at the MEC. One drink of alcohol 
was defined as a 12 oz. beer, a 5 oz. glass of wine, or one and a half ounces of liquor. Sexual 
behavior variables included ever having sex (vaginal, oral, and anal), age of sex debut, life time 
opposite sex partners and same sex partners, age of first oral sex, having new sex partners in past 
12 months, and frequencies of sex (vaginal/anal). Additional variables for status of sexual 
transmitted diseases, such as ever been told by doctor of having HPV, herpes, genital wart, 
gonorrhea, and chlamydia, were included as well. 
2.3 Laboratory Methods 
2.3.1 Oral Specimen Collection  
Oral sample were collected by a 30-second oral rinse and gargle with SCOPETM 
mouthwash (10ml) at MEC. Subjects alternate a series of three, five second rinses and five 
second gargles and then expectorated into a sterile collection tube. De-identified specimens were 
stored at 4°C and shipped to Oral HPV Detection Laboratory (OHD), Polaris Innovation Center, 
Polaris, Ohio, for HPV detection [44].  
2.3.2 DNA Isolation  
Cells in samples were collected by centrifuge and lysed in Puregene cell lysis solution 
followed by DNase-free RNase and proteinase K digestion using the Qiagen Virus/Bacteria Midi 
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kit and Pathogen Complex 800 program on the Qiasymphony SP instrument (Qiagen). DNA was 
eluted in 60 μL of AVE buffer and quantified using NanoDrop 8000 (ThermoFisher Scientific) 
[44, 45].  
2.3.3 HPV Genotyping Test   
HPV detection and genotyping were performed using Linear Array (LA) genotyping 
assay (Roche Diagnostics). The assay detects 37 HPV types using HPV L1 consensus 
polymerase chain reaction (PCR) with PGMY09/11 primer pools and primers for β-globin as an 
internal control for multiplex amplification. PCR product were denatured in NaOH and 
hybridized to an immobilized HPV probe array for detection of β-globin and genotyping of 37 
HPV types, including HRHPV types (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 
73, 82) and LRHPV types (6, 11, 40, 42, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 81, 82 subtype 
IS39,83, 84, 89 [cp6108]) (Roche Linear Array HPV Genotyping Test; Roche Molecular 
Systems) [46]. The XR probe on the LA HPV strip had cross reaction with HPV 33, 35, 52 and 
58 and required further test. Samples positive for HPV XR, 33, 35, and 58 were tested for HPV 
52 using type-specific TaqMan real time PCR to determine HPV 52 status. Samples negative for 
both β-globin and HPV were considered as insufficient and were excluded from further analysis 
[47]. All procedures were performed according to the NHANES quality assurance and quality 
control (QA/QC) protocols that meet the 1988 Clinical Laboratory Improvement Act (CLIA) 
mandates [44]. 
2.4 Statistical Analysis 
NHANES 2013-2014 MEC respondents aged 18-69 years with valid oral HPV test results 
(n=4724) were included in the analysis. The NHANES 2013-2014 MEC sample weights were 
used to account for the complex survey design and to generate unbiased estimate of prevalence. 
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Data manipulation, variable creation, data merging and analysis were performed using SAS 
version 9.3 (SAS Institute). SAS survey procedures were used for all statistical analysis to 
account for complex survey features such as stratification, clustering, and weights. Variance was 
estimated using Taylor Series Linearization (TSL) method to account for the complex cluster 
survey design. To adjust for nonresponses and account for the unequal probabilities of selection, 
all estimates were analyzed using 2-year weighted variables constructed from the MEC 
examination weights provided with the dataset (WTMEC2YR) [41]. The dataset has 15 strata 
with 2 clusters per strata (SDMVSTR, SDMVPSU). HPV prevalence with Confidence Intervals 
(CIs) were estimated using a logit transformation and generated using SAS surveymeans or 
surveyfreq procedures. 
Overall oral HPV prevalence with any types was estimated by sociodemographic and 
sexual behavior characteristics. Medical conditions, including status of sexual transmitted 
diseases and vaccination history of HPV, were included as well. The prevalence of HR- and LR- 
HPV infections were estimated by the same characteristics. We also evaluated HPV prevalence 
within characteristics such as gender and race stratified by age group. Weighted estimates of 
prevalence with 95% Confidence Interval (95% CI) were presented. Rao-Scott χ2 test was used 
to examine the independence between HPV prevalence and selected characteristics for complex 
survey design, in which test are no longer follow the same χ2 distribution under null hypothesis 
[44, 48, 49].  
Logistics regression models were used to explore the relationship between HPV infection 
and demographic or behavioral characteristics. Characteristics that was associated with HPV 
infection in univariate analysis was selected for multivariate logistic analysis. Multiple models 
were constructed to evaluate the association between HPV infection (overall HPV, HRHPV, 
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LRHPV, and HPV16) and selected characteristics. Some characteristics with collinearity such as 
sexual behaviors were analyzed separately. Interactions between characteristics of interest were 
examined by pairwise logistic regression tests. Odds Ratios (OR) with 95% CI were used to 
evaluate risks. Wald χ2 test was used to evaluate associations between the selected characteristics 
and HPV infection. Two-tailed P values less than 0.05 was considered as statistically significant 
for all analysis in this study. Logistics regression analysis was conducted using surveylogistic 
procedure in SAS 9.3.    
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3 RESULTS 
3.1 Overall Oral HPV Prevalence  
The weighted prevalence for oral HPV infection was estimated based on HPV DNA 
positivity using 4724 participants in the dataset. The overall oral HPV prevalence of any types in 
U.S. population aged 18-69 years was 7.18% (95% CI, 5.9%-8.4%). This represented 14,219,994 
people with this condition, based on the weight variable WTMEC2YR that summed to 
population at that time. The HPV infection prevalence was estimated as 4.5% (95% CI, 3.05%-
4.97%) for HRHPV and 3.5% (95% CI, 3.09%-4.58%) for LRHPV, respectively. The prevalence 
of type-specific oral HPV infections was shown in Figure 1. 36 of the 37 types covered by LA 
assay, except for HPV type 64, were detected from the NHANES samples collected during 2013-
2014. The prevalence of individual HPV types ranged from 0.005% to 0.96%. The most 
prevalent HPV type was HPV16 (0.97%; 95% CI, 0.7%-1.23%). Of the 359 HPV positive 
samples among the 4724 subjects, 281 (78.3%) were single HPV infection, and 78 (21.7%) were 
multiple infections ranging from 2 to 6 types, representing 11 and 3 million people, respectively 
(Table 2).  
    
Figure 1 Weighted prevalence of Oral HPV infection by individual HPV types in U.S. 
population aged18-69 years 
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Table 2 Frequencies of single and multiple infections of oral HPV in U.S. population aged 18-69 
years 
No. of HPV types Frequency Weighted Frequency Percent 
1 281 11,157,651 5.63 
2 62 2,111,244 1.07 
3 12 586,275 0.30 
4 3 350,246 0.18 
6 1 14,578 0.0074 
0 4,365 183,829,791 92.80 
Total 4,724 198,049,785 100.0 
 
3.2 Oral HPV Prevalence by Demographic and Life Style Characteristics 
The prevalence of oral HPV infection was analyzed by demographic characteristics (Table 
3). Bivariate analysis revealed that the distribution of any HPV infection was significantly 
different across several characteristics including gender, country of birth, race, education, marital 
status, alcohol use, and tobacco use (Table 3). The prevalence of any oral HPV infection was 
significantly higher (3.4 folds) in males (11.1%; 95% CI, 8.8%-13.3%) than that in females 
(3.3%; 95% CI, 4.3%-6.8%). Non-Hispanic Black had the highest overall prevalence (9.5%; 95% 
CI, 7.8%-11.3%), followed by Non-Hispanic White (7.4; 95% CI, 5.9%-8.9%). Non-Hispanic 
Asian had the lowest prevalence (2.9; 95% CI, 7.8%-11.3%). Overall HPV prevalence was lower 
among married people (6.4%; 95% CI, 4.9%-7.9%), compared to those who were not in marriage 
status (9.6% for widow/divorced/separated; 8.3% for never married). People born in U.S. had 
higher prevalence (7.5%; 95% CI, 6.1%-9%) than those who were born in other countries (5.1%; 
95% CI, 3.3%-7%). Significant difference in distribution across education levels was observed as 
well (Table 3). Overall prevalence of any HPV infection appeared to be associated with alcohol 
and tobacco use. HPV prevalence was positively correlated to the number of alcohol consumed 
per day (Table 3). People who drank 4 alcohols per day had HPV prevalence (13%; 95% CI, 
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9.2%-16.8%) nearly twice as high as those who didn’t drink (6.7%; 95% CI, 5%-8.4%). HPV 
prevalence was higher in people who smoked at time of interview (12.9%; 95% CI, 9.7%-16.1%) 
than non-smokers (7.1%; 95% CI, 5.1%-9.2%). Similar to alcohol use, HPV prevalence was 
positively correlated to the number of cigarette consumed per day (Table 3). The age starting 
smoking seemed to have little impact on oral HPV prevalence. Oral HPV prevalence seemed to 
be higher in people with decayed teeth and gum disease. However, these variables had low 
number participants who responded “No” to the questions and did not had P value calculated. 
Oral HPV prevalence appeared to be lower in people with HPV vaccination compared to those 
who did not received vaccination (Table 3). The prevalence of HRHPV infection and LRHPV 
infection each showed similar distribution patterns across characteristics as any HPV infection. 
Only two variables, gender and using more than 4 alcohol/day, showed significantly different 
prevalence distribution patterns for all three categories of HPV (P<0.05) (Table 3).  
Table 3 Weighted prevalence of oral HPV among U.S. adults (18-69 years) by demographic 
characteristics, National Health and Nutrition Examination Survey, 2013-2014 
Characteristic   Any HPV 
HRHPV (with or 
without LRHPV)  LRHPV (with or without HRHPV)  Sample 
size 
Prevalence 
(95%CL) P-value
a
 
Prevalence 
(95%CI) P-value
a
 
Prevalence (95%CI) P-value
a
 
Total 4724 7.1(5.9-8.4) 
 
4(3-4.9) 
 
3.8(3-4.5)  Age  
      
 
18-24 805 4.9(2.7-7.2) 0.5871 2.9(1-4.9) 0.5034 2(1-3) 0.3043 25-29 410 6.4(3.3-9.6) 
 
4.1(1-7.2) 
 
2.9(1.2-4.6)  30-34 473 6.1(3.5-8.7) 
 
3.6(1.6-5.6) 
 
2.8(0.8-4.7)  35-39 426 6.9(4.5-9.3) 
 
3.2(1.1-5.4) 
 
4(1.3-6.6)  40-44 479 7.6(3.5-11.6) 
 
3.7(0.9-6.5) 
 
4.5(1.8-7.3)  45-49 437 7.2(3.1-11.3) 
 
4.5(1.6-7.3) 
 
3.3(0.9-5.6)  50-54 433 9.4(5-13.8) 
 
6.4(3.3-9.6) 
 
3.9(1.4-6.4)  55-59 415 9.1(4.8-13.5) 
 
5(1.9-8.1) 
 
5.1(2.5-7.6)  60-64 476 8.3(2.7-13.9) 
 
2.8(1-4.5) 
 
6.8(1.9-11.8)  65-70 370 6.2(3.1-9.4) 
 
3.6(1.1-6) 
 
4(1-6.9)  Gender 
  
* 
 
* 
 
* 
M 2278 11.1(8.8-13.3) <.0001 6.6(4.9-8.3) <.0001 5.5(4.3-6.8) <.0001 F 2446 3.3(2.5-4.1) 
 
1.4(0.9-1.9) 
 
2.1(1.4-2.8)  
Country of birth 
  
* 
 
* 
 
 
US 3405 7.5(6.1-9) 0.0163 4.4(3.2-5.5) 0.002 3.9(2.9-4.8) 0.5894 Others 1316 5.1(3.3-7) 
 
2(0.9-3.1) 
 
3.4(2-4.8)  Missing 3 0(0-0) 
 
0(0-0) 
 
0(0-0)  Racec  
  
* 
   
* 
Mexican American 708 6.4(3.8-9.1) 0.0044 2.9(1.1-4.8) 0.1055 4(2.1-6) 0.0164 
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Other Hispanic 434 5(2.8-7.1) 
 
3.3(1.6-5.1) 
 
2.3(0.7-3.9)  NHW 1865 7.4(5.9-8.9) 
 
4.3(2.9-5.6) 
 
3.7(2.9-4.6)  NHB 1005 9.5(7.8-11.3) 
 
4.7(3.8-5.6) 
 
5.7(4-7.4)  NH Asian 547 2.9(1.7-4) 
 
1.9(0.8-3) 
 
1.2(0.5-1.8)  Other 165 6.5(2.3-10.7) 
 
2.9(0.2-5.5) 
 
4.6(1.2-8)  Education  
  
* 
   
* 
Less than high school 295 6.7(3.4-9.9) 0.0003 2.9(0.3-5.5) 0.0633 3.8(1.8-5.7) 0.0051* High school or equivalent 1558 9.8(7.5-12.2) 
 
4.9(3.8-6.1) 
 
5.9(4-7.9)  College or above 2541 6.1(5-7.3) 
 
3.7(2.6-4.8) 
 
2.9(2.1-3.7)  Missing 330 2.7(0.9-4.4) 
 
1.2(0-2.5) 
 
1.4(0.1-2.6)  
Income poverty ratio 
      
 
<1.0 1076 8.5(6.6-10.3) 0.5978 4.3(3.3-5.3) 0.814 5(3.6-6.4) 0.1143 ≥1.0 to <2.0 1067 7.2(4.4-10) 
 
3.7(2-5.3) 
 
4.2(2.1-6.2)  ≥2.0 to <3.0 576 6.5(3-10.1) 
 
4.7(2.1-7.2) 
 
2(0.7-3.4)  ≥3.0 1651 6.5(4.4-8.7) 
 
4(2.5-5.5) 
 
3.2(2-4.5)  Missing 354 9.2(3.5-14.9) 
 
2.3(1-3.5) 
 
7.3(1.5-13.1)  Marital status 
  
* 
   
* 
Married/living with 
partners 
2628 6.4(4.9-7.9) 0.0294 3.7(2.5-4.9) 0.3151 3.2(2.4-4) 0.0148* 
Widow/divorced/separated 792 9.6(6.9-12.4) 
 
5(2.9-7.1) 
 
5.8(3.7-8)  
Never married 974 8.3(6.5-10.2) 
 
4.5(3-6) 
 
4.6(3.1-6.1)  Missing 330 2.6(0.9-4.4)   1.2(0-2.5)   1.4(0.1-2.6)   No. Alcohol/day   *    * No alcohol 1003 5.8(4.2-7.4) 0.0441 2.3(1.6-3) 0.055 3.7(2-5.3) 0.048 ≥2 to <4/day 1632 7.3(5.1-9.5)  4.5(2.9-6.1)  3.6(2.6-4.5)  ≥4 to <8/day 367 11.8(6.2-17.3)  6.8(2.6-11)  6.6(3.3-9.9)  >8/day 102 14.9(5.8-24)  6.2(0.1-12.4)  9.4(4.3-14.4)  Missing 1620 6(4.1-7.9)  3.6(2.3-5)  2.9(2-3.9)  More than 4 alcohol/day   *  *  * Yes 610 13(9.2-16.8) 0.004 7.3(4.8-9.8) 0.0106 6.8(3.5-10) 0.0327 No 3097 6.7(5-8.4)  3.9(2.5-5.2)  3.5(2.8-4.2)  Missing 1017 4.3(2.6-6)  1.7(0.7-2.8)  2.7(1.6-3.8)  Currently smoking   *  *   Yes 1052 12.9(9.7-16.1) 0.0004 8.2(5.7-10.7) <.0001 6(4.4-7.6) 0.3001 No 908 7.1(5.1-9.2)  2.8(1.7-3.9)  4.5(2.4-6.7)  Missing 2764 5(4-6.1)  2.8(2.3-3.3)  2.7(1.8-3.6)  Age starting smoking 
regularly 
       
Never smoke 94 9.1(1.9-16.4) 0.4011 3.9(-0.7-8.6) 0.3968 5.1(-0.8-11.2) 0.432 ≤18 1289 9.1(6.3-11.9)  5.1(3-7.3)  4.7(3.2-6.1)  19-30 528 12(8.5-15.5)  6.9(4.3-9.5)  6.3(3.7-8.8)  >30 43 18.2(-1.4-37.9)  5.6(0-11.3)  14.1(-4.9-33.1)  Missing 2770 5(4-6.1)  2.8(2.3-3.3)  2.7(1.8-3.6)  No. Cigarette/day        ≤1 84 8.3(1-15.6) 0.0855 3.9(-0.6-8.6) 0.2856 4.3(-0.7-9.3) 0.1344 ≥2 to <10/day 405 9.9(5-14.8)  6.3(1.6-11)  4.1(2.1-6.2)  ≥10 to <20/day 315 15.3(12.1-18.6)  10.5(6.4-14.6)  6.4(3.5-9.4)  ≥20/day 236 15.6(9.2-21.9) 9.7(3.8-15.5)  8.4(5.1-11.8)  Missing 3684 5.6(4.6-6.6)  2.8(2.2-3.4)  3.2(2.5-3.9)  Decayed teeth        Yes 1590 9.7(7.2-12.2) 0.0961 4.6(2.8-6.3) NAb 5.8(4-7.5) 0.3822 No 10 2.9(-3.5-9.4)  0(0-0)  2.9(-3.5-9.4)  Missing 3124 6.1(4.9-7.2)  3.7(2.8-4.6)  2.9(2.3-3.6)  Gum disease        
Yes 1532 9.9(6.9-12.8) 0.9917 4.6(2.9-6.4) 0.6309 6.2(4.2-8.2) NAb 
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No 7 9.8(-13-32.6)  9.8(-13-32.6)  0(0-0)  Missing 3185 6.1(4.9-7.3)  3.7(2.7-4.7)  2.9(2.3-3.5)  HPV vaccination        Yes 390 5.2(3.7-6.6) 0.0573 2.8(1.2-4.3) 0.0601 2.4(0.8-4.1) 0.2218 No 3279 7.3(5.4-9.3)  4.3(3-5.6)  3.6(2.6-4.7)  Missing 1055 7.1(3.9-10.4)   3.2(1.7-4.7)   4.9(1.8-8)   Note: CI: Confidence Interval.  
a
Rao-Scott χ
2
 test P values for distribution of prevalence among characteristics, missing values were 
excluded from the analysis. 
b
P values were not determined due to lack of samples in one level of the characteristics. * P<0.05. 
c
NHW, Non-Hispanic White, NHB, Non-Hispanic Black, NH Asian, Non-Hispanic Asian. 
 
 
HPV prevalence over age was shown in Figure 2 and Figure 3. The prevalence for any 
HPV infection showed a trend to increase by age and reached to a peak (9.4%; 95%CI, 5%-
13.8%) in people aged 50-54 and decreased gradually in later ages (Figure 3A and Table 3). 
Notably, the prevalence of HRHPV and LRHPV by age appeared to follow bimodal patterns. 
The first peak of infection for HRHPV were observed among people aged 25-29 (4.1%; 95%CI, 
1%-7.2%), and the second peak appeared in people aged 50-54 (6.4%; 95%CI, 3.3%-9.6%) 
(Figure 3B). Unlike HRHPV, peaks for LRHPV prevalence appeared in later ages with first peak 
in people aged 40-44 (4.5%; 95%CI, 1.8%-7.3%) and second peak in people aged 60-64 (6.8%; 
95%CI, 1.9%-11.8%) (Figure 3C). The prevalence of HPV16, the most oncogenic type, was 
shown in Figure 4. People aged 45-49 years, 55-59 years, and 65-69 years showed higher 
prevalence compared to people in other age groups.  
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(A) Overall Oral HPV prevalence in percentage of any types; (B) Oral HPV prevalence in 
percentage of high-risk types; (C) Oral HPV prevalence in percentage of low-risk types. Error 
bars indicate 95% CI. 
 
Figure 2 Weighted oral HPV prevalence by age (14-69 years) 
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(A) Overall Oral HPV prevalence any types; (B) Oral HPV prevalence of high-risk types; (C) 
Oral HPV prevalence of low-risk types. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Weighted oral HPV prevalence by age group 
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3.3 Oral HPV Prevalence by Sexual History 
The oral HPV prevalence classified by sexual behavior and sexual transmitted diseases 
was shown in Table 4. The distribution of any HPV infection was significantly different for 6 of 
the 10 characteristics (p<0.05) including ever had vaginal/oral/anal sex, age of sex debut, number 
of lifetime opposite or same sex partners. HRHPV distribution differed significantly across the 
Figure 4 Weighted prevalence of HPV16 by age 
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categories of four factors, ever had vaginal/oral/anal sex, ever had anal sex, age of sex debut, and 
number of lifetime opposite sex partners. For LRHPV, only 3 factors, ever had anal sex, age of 
sex debut, and number of lifetime opposite sex partners, showed significant difference in the 
infection distribution across categories of these factors (Table 4).  
The prevalence of Oral HPV (any types, HRHPV, and LRHPV) was higher in people 
who had sex experience (vaginal, oral and anal), compared to those who reported no sex 
experience.  People who started sex before 18 years of age had higher overall HPV prevalence 
(9.8%; 95%CI, 7.6%-11.9%) than those who started sex at 18 years or older (3.7%; 95%CI, 
2.7%-4.7%). Among those who had active sexual activities, the HPV prevalence was correlated 
with number of opposite sex partners. People who had more than 10 partners had oral HPV 
prevalence of 14.6% (95%CI, 9.9%-19.3%), 9.5% (95%CI, 6.4%-12.6%), and 6.8% (95%CI, 
4.4%-9.1%) for any type, HR-, and LR- HPV, respectively (Table 4). Interestingly, people who 
had same sex partners showed a different pattern. The highest prevalence was observed in people 
who had 5-10 same sex partners (32.7%; 95%CI, 8.2%-57.2%) for any HPV, 16.2% (95%CI, -
5.9%-38.4%) for HRHPV, and 16.4 % (95%CI, -4.7%-37.7%) for LRHPV) (Table 4). We 
observed relative high prevalence in people who reported having sex once in past 12 months 
(12.1 % for any HPV, 6.4% for HRHPV, and 6.2% for LRHPV). For people who had sex 
between 2 to 103 times in past 12 months had lower prevalence compared to those who had sex 
only once or more frequently (>103 times) (Table 4). Whether a person had new partners in past 
12 months seemed to have little impact on HPV infection. Sexual transmitted disease status 
informed by doctors had mixed results of HPV prevalence (Table 4). HPV prevalence was higher 
in people who had chlamydia infection (9.4%) than those who did not. Prevalence of HPV 
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infection among people who did not respond (missing) to questions about their sexual history 
was reported as well to reflect the overall prevalence in the population (Table 4).  
Table 4 Weighted prevalence of oral HPV among U.S. adults aged 18-69 years by sexual 
behavior, National Health and Nutrition Examination Survey, 2013-2014 
Characteristic   Any HPV    
HRHPV (with or without 
LRHPV)  
LRHPV (with or without 
HRHPV)  
Sample 
Size 
Prevalence 
(95%CI) 
P valuea Prevalence (95%CI) 
P valuea Prevalence (95%CI) 
P valuea 
Total 4724 7.1(5.9-8.4)  4(3-4.9)  3.8(3-4.5)  
Ever had 
vaginal/anal/oral sex   * *    
Yes 4115 7.2(5.8-8.7) 0.003 4.1(3-5.2) <.0001 3.8(3-4.6) 0.1298 
No 239 2.5(0-5)  0.4(-0.4-1.3)  2(0-4.2)  
Missing 370 8.5(4.4-12.6)  3.7(0.6-6.9)  4.7(2.1-7.4)  
Ever had vag. sex        
Yes 4030 7.1(5.7-8.5) 0.5906 4(3-5.1) 0.3859 3.7(2.9-4.6) 0.9796 
No 324 5.9(1.3-10.6)  3(0.1-5.8)  3.7(0.4-6.9)  
Missing 370 8.4(4.2-12.6)  3.6(0.4-6.8)  4.7(2-7.4)  
Ever had oral sex        
Yes 3362 7.6(6-9.1) 0.0261 4.3(3.2-5.5) 0.0575 4(3.1-5) 0.0197 
No 982 4.8(2.5-7.1)  2.6(0.9-4.4)  2.2(0.9-3.5)  
Missing 380 7.4(4.5-10.3)  2.8(0.4-5.1)  4.6(2-7.3)  
Ever had anal sex   *  *   
Yes 1580 9(7.1-10.9) 0.0042 5.4(3.8-7.1) 0.0098 4.5(3.5-5.5) 0.0524 
No 2763 5.9(4.1-7.6)  3.1(1.9-4.4)  3.2(2.1-4.3)  
Missing 381 7.5(4.6-10.4)  2.8(0.4-5.2)  4.7(2-7.3)  
Age of sex debut   *  *  * 
<18 2403 9.8(7.6-11.9) <.0001 5.5(3.6-7.4) 0.0014 5.2(4.1-6.2) <.0001 
≥18 1704 3.7(2.7-4.7)  2.3(1.6-2.9)  1.8(1.1-2.5)  
Missing 617 5.7(3.9-7.5)  1.9(0.4-3.5)  3.7(2.2-5.3)  
No. Life time 
heterosexual partners   *  *  * 
0 partner 272 5.5(0.4-10.6) <.0001 2.2(-0.8-5.2) <.0001 3.5(0-7) 0.0005 
1 partner 642 1.8(0.2-3.3)  0.6(-0.1-1.4)  1.1(0-2.3)  
>1 to ≤5 1448 3.6(2.3-4.9)  1.7(1-2.5)  2.1(1-3.2)  
>5 to ≤10 903 7.2(4.9-9.6)  3.6(2-5.3)  4.3(2.5-6.1)  
>10 1101 14.6(9.9-19.3)  9.5(6.4-12.6)  6.8(4.4-9.1)  
Missing 358 7.7(4.6-10.9)  2.8(0.3-5.3)  4.9(2.1-7.7)  
No. of Life time 
homosexual partners   *     
1 partner 101 7.6(1.4-13.9) 0.0427 3.5(-1.4-8.6) 0.1014 4(-0.8-9) 0.3464 
>1 to ≤5 142 5.6(1.4-9.9)  3.2(0.3-6.1)  2.9(-0.5-6.3)  
>5 to ≤10 23 32.7(8.2-57.2)  16.2(-5.9-38.4)  16.4(-4.7-37.7)  
>10 35 28.5(6.7-50.4)  23.2(1.5-45)  6.2(-0.5-13)  
Missing 4423 6.8(5.6-8)  3.7(2.9-4.6)  3.7(2.9-4.5)  
Age of 1st oral sex        
<18 529 5(1.6-8.3) 0.2854 3.7(0.7-6.7) 0.1544 1.5(0.1-2.9) 0.5957 
≥18 995 3.3(2-4.6)  1.6(0.9-2.3)  2(0.9-3.1)  
Missing 3200 8.9(7.3-10.4)   4.8(3.7-5.9)   4.9(3.8-5.9)   
New sex partner in 
past year        
Yes 575 9.9(6.4-13.4) 0.0741 6.4(3.4-9.3) 0.1042 4.7(2.7-6.6) 0.2164 
No 2353 6.9(4.6-9.2)  4(2.6-5.5)  3.3(1.9-4.6)  
25 
Missing 1796 6.4(4.4-8.5)  2.9(1.9-3.9)  4.3(2.3-6.3)  
Frequency of 
vaginal/anal sex in 
past year 
       
Never 89 6.4(1-11.8) 0.3554 4.4(0.9-7.8) 0.6663 3.6(-0.1-7.5) 0.7701 
Once 129 12.1(4.1-20.1)  6.4(-0.3-13.2)  6.2(0.1-12.2)  
2-11 times 683 7(3-11)  4.2(1-7.3)  3.4(1.1-5.7)  
12-51 times 984 7(4.1-9.9)  3.9(1.5-6.4)  3.6(2.4-4.8)  
52-103 times 612 6.6(3.6-9.5)  4.3(2-6.6)  2.9(1.2-4.7)  
104-364 times 370 9.1(4.7-13.4)  5.7(1.9-9.4)  3.8(1.4-6.3)  
≥365 times 39 19.8(3.7-36)  12.8(-2.1-27.8)  7(-2.7-16.8)  
Missing 1818 6.4(4.4-8.5)  2.9(2-3.9)  4.2(2.2-6.2)  
 Herpes status by 
doctor     *   
Yes 124 5.1(0.9-9.2) 0.2321 1.7(-0.4-3.9) 0.0226 3.3(-0.4-7.1) 0.9533 
No 3228 7.3(5.3-9.3)  4.5(3.1-5.9)  3.4(2.4-4.4)  
Missing 1372 6.8(4.3-9.4)  2.7(1.5-3.9)  4.9(2.4-7.5)  
Genital warts 
status by doctor   *  *   
Yes 124 3.5(1.2-5.8) 0.0003 2.1(0.4-3.9) 0.0183 1.9(-0.1-4) 0.0979 
No 3229 7.4(5.4-9.4)  4.5(3.1-5.8)  3.5(2.4-4.5)  
Missing 1371 6.8(4.3-9.4)  2.7(1.5-3.9)  4.9(2.4-7.5)  
Chlamydia status 
by doctor        
Yes 45 9.4(1.1-17.6) 0.5374 4.5(-0.3-9.4) 0.9435 6.3(-1.1-13.8) 0.3953 
No 3307 7.2(5.3-9.1)  4.4(3-5.7)  3.4(2.4-4.4)  
Missing 1372 6.8(4.3-9.4)  2.7(1.5-3.9)  4.9(2.4-7.5)  
Note: CI: Confidence Interval. 
a
Rao-Scott χ
2
 test P values for distribution of prevalence among characteristics, missing values were 
excluded from the analysis. 
* P<0.05. 
 
3.4 Univariate Analysis of Factors Associated with HPV Infection 
The association between any type HPV infection and 26 demographic and behavioral 
characteristics was evaluated with unadjusted odds ratio (OR) from univariate analysis (Table 5). 
Of the 26 characteristics, 16 were associated with HPV infection. Factors with p value less than 
0.0001 included age, gender, race, education level, age of sex debut, and number of life time sex 
partners. Categories or levels within each associated characteristic conferred various degrees of 
potential risk on HPV infection. The unadjusted ORs were correlated with prevalence of HPV 
infection presented in Table 3. The factors conferring high risks included males, heavy alcohol 
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and tobacco use, having sex experience, high number of life time sexual partners, and high 
frequency of sex. 
Table 5 Univariate analysis of characteristics associated with oral HPV infection (any type) in 
U.S. population aged 18-69 years 
Characteristic Unadjusted OR (95%CI) P value 
Age   
18-24 1[reference]  
25-29 1.32(0.69-2.52) <0.0001 
30-34 1.25(0.71-2.19)  
35-39 1.42(1.01-2.02)  
40-44 1.57(0.89-2.76)  
45-49 1.48(0.82-2.67)  
50-54 1.98(1.36-2.9)  
55-59 1.92(0.95-3.89)  
60-64 1.73(0.65-4.63)  
65-70 1.28(0.56-2.89)  
Gender 0(0-0)  
M 3.55(2.72-4.65) <0.0001 
F 1[reference]  
Country of birth   
US 1.5(1.03-2.17) 0.0321 
Others 1[reference]  
Race   
Mexican American 0.86(0.54-1.36) <.0001 
Other Hispanic 0.66(0.43-1)  
NHW 1[reference]  
NHB 1.32(1.07-1.62)  
NH Asian 0.37(0.25-0.55)  
Other 0.87(0.47-1.6)  
Education   
Less than high school 1[reference]  
High school or equivalent 1.52(0.9-2.56) 0.0001 
College or above 0.91(0.53-1.54)  
Inpovr   
<1.0 1[reference]  
≥1.0 to <2.0 0.84(0.54-1.31) 0.2682 
≥2.0 to <3.0 0.76(0.44-1.31)  
≥3.0 0.75(0.56-1.02)  
Marital status   
Married/living with 
partners 0.75(0.6-0.94) 0.0166 
Widow/divorced/separated 1.16(0.81-1.67)  
Never married 1[reference]  
No. Alcohol/day   
No alcohol 1[reference]  
≥2 to <4/day 1.28(0.79-2.08) 0.0027 
≥4 to <8/day 2.16(1.11-4.2)  
>8/day 2.82(1.38-5.77)  
More than 4 per day   
Yes 2.08(1.32-3.25) 0.0014 
No 1[reference]  
Currently smoking   
Yes 1.91(1.35-2.71) 0.0002 
No 1[reference]  
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Age starting smoking 
regularly 
  
Never smoke 1[reference]  
≤18 0.99(0.42-2.34) 0.4369 
19-30 1.36(0.53-3.44)  
>30 2.2(0.69-7.02)  
No. Cigarettes/day 0(0-0)  
≤1 1[reference]  
≥2 to <10/day 1.22(0.44-3.33) 0.0741 
≥10 to <20/day 2(0.8-5.04)  
≥20/day 2.04(0.86-4.8)  
Ever had 
vaginal/anal/oral sex 
  
Yes 3.03(1.14-8.01) 0.0254 
No 1[reference]  
Ever had vaginal sex   
Yes 1.21(0.56-2.6) 0.6182 
No 1[reference]  
Ever had oral sex   
Yes 1.62(0.99-2.65) 0.0531 
No 1[reference]  
Ever had anal sex   
Yes 1.57(1.14-2.17) 0.0055 
No 1[reference]  
Age of sex debut   
Yes 2.78(2.01-3.85) <.0001 
No 1[reference]  
No. Life time 
heterosexual partners 
  
0 partner 1[reference]  
1 partner 0.32(0.11-0.91) <.0001 
>1 to ≤5 0.64(0.23-1.81)  
>5 to ≤10 1.33(0.43-4.07)  
>10 2.93(1.28-6.72)  
No. of Life time 
homosexual partners  
 
1 partner 1[reference]  
>1 to ≤5 0.72(0.24-2.17) <.0001 
>5 to ≤10 5.85(1.28-26.63)  
>10 4.81(1.24-18.55)  
Age of 1st oral sex   
<18 1.52(0.77-2.99) 0.2202 
≥18 1[reference]  
New sex partner in past 
year 
  
Yes 1.47(0.99-2.18) 0.0547 
No 1[reference]  
Frequency of 
vaginal/anal sex in past 
year 
  
never 1[reference]  
once 2.01(0.69-5.81) 0.0125 
2-11 times 1.1(0.34-3.5)  
12-51 times 1.1(0.45-2.68)  
52-103 times 1.03(0.42-2.53)  
104-364 times 1.46(0.62-3.44)  
≥365 times 3.62(0.89-14.61)  
 HPV status by doctor   
Yes 1.37(0.52-3.6) 0.5207 
No 1[reference]  
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 Herpes status by doctor   
Yes 1(1.06-0.3) 0.3011 
No 1[reference]  
Genital warts status by 
doctor 
  
Yes 0.46(0.27-0.78) 0.0044 
No 1[reference]  
Chlamydia status by 
doctor 
  
Yes 1.32(0.61-2.85) 0.4657 
No 1[reference]   
 
 
3.5 Multivariable Analysis of Factors Associated with Oral HPV Infection  
In multivariable analysis, ORs for HPV infection were adjusted for 9 characteristics, age, 
gender, country of birth, race, education, marital status, number of alcohols consumed per day, 
whether or not smoke at the time of interview, and age of sex debut. Categories in each 
characteristic showed different risks for HPV infection (any types, HRHPV, and LRHPV) (Table 
6). Four characteristics (age, gender, whether or not smoke at the time of interview, and age of 
sex debut) were independently associated with any HPV infection (p<0.05). Five factors (age, 
gender, country of birth, whether or not smoke at the time of interview, and age of sex debut) 
were associated with HRHPV infection (p<0.05). LRHPV had six independently associated 
factors (age, gender, race, education level, marital status, and age of sex debut) (p<0.05). Three 
characteristics, age, gender, and age of sex debut, were significantly associated with HPV 
infection of all types, HRHPV and LRHPV. Two factors, country of birth, number of alcohols 
used per day seemed to have little independent risks. Other factors exhibited mixed results 
(Table 6). People who started sex before 18 years old were at least 3 times more likely to be 
HPV positive than those who started sex after 18 years old (adjusted OR, 3.95 for overall HPV, 
3.65 for HRHPV, and 3.68 for LRHPV). Interestingly, use of tobacco had risks for overall and 
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HR HPV but not for LRHPV, while race, education and marital status were associated with 
LRHP infection only (Table 6). 
Among the age groups, people aged 65-70 years had the highest risk of being infected by 
any HPV or HRHPV (adjusted OR, 3.01 for all types and 2.14 for HRHPV). People aged 30-34 
years were less likely to be infected by HPV (adjusted OR, 0.69 for all types and 0.22 for 
HRHPV) (Table 6). Persons aged 25 and older were more likely to had LRHPV infection 
(adjusted OR range: 2.33-9.54) compared to those of 18-24 years of age. Notably, people aged 
60-64 were 9.54 times were more likely to be infected by LRHPV than those in any other group 
(Table 6).  
Table 6 Multivariable analysis of characteristics independently associated with HPV infection 
among people aged 18-69 years 
 Characteristic 
Any HPV   HRHPV   LRHPV   
Adj. OR (95%CI) P value Adj. OR (95%CI) p value Adj. OR (95%CI) P value 
Age             
18-24 1[Reference] 0.0004 1[Reference] 0.0007 1[Reference] <.0001 
25-29 1.38(0.42-4.55)  1.28(0.37-4.44)  2.33(0.32-16.61)  
30-34 0.69(0.18-2.59)  0.22(0.04-1.1)  2.82(0.44-17.89)  
35-39 1.7(0.57-5.01)  0.68(0.17-2.61)  4.99(0.71-34.76)  
40-44 2.23(0.64-7.81)  0.97(0.32-2.88)  6.32(0.52-76.07)  
45-49 2.34(0.8-6.78)  1.42(0.27-7.3)  5.53(1.29-23.7)  
50-54 2.53(1.09-5.89)  1.49(0.56-3.9)  6.58(1.36-31.82)  
55-59 2.62(0.59-11.63)  1.12(0.19-6.39)  7.77(1.15-52.51)  
60-64 2.65(0.55-12.64)  0.76(0.17-3.39)  9.54(1.2-75.34)  
65-70 3.01(0.93-9.76)  2.14(0.63-7.2)  5.94(0.86-40.91)  
Gender       
M 3.41(1.77-6.54) 0.0002 3.26(1.36-7.79) 0.0079 2.98(1.59-5.57) 0.0006 
F 1[Reference]  1[Reference]  1[Reference]  
Country of birth       
US 1.06(0.3-3.64) 0.927 2.88(1.18-7.04) 0.0197 0.49(0.09-2.71) 0.4208 
Others 1[Reference]  1[Reference]  1[Reference]  
Race       
Mexican American 0.87(0.26-2.9) 0.784 1.28(0.37-4.39) 0.5142 0.75(0.15-3.76) 0.0471 
Other Hispanic 0.59(0.18-1.96)  1.52(0.6-3.82)  0.19(0.03-1.04)  
NHW 1[Reference]  1[Reference]  1[Reference]  
NHB 1.22(0.84-1.78)  0.9(0.45-1.78)  1.38(0.88-2.16)  
NH Asian 0.82(0.25-2.62)  2.75(0.58-12.92)  0.17(0.02-1.26)  
Other 0.56(0.13-2.37)  0.53(0.12-2.23)  0.92(0.15-5.36)  
Education       
Less than high school 1[Reference] 0.0892 1[Reference] 0.6569 1[Reference] 0.0071 
High school or equivalent 3.49(0.98-12.44)  2.21(0.4-12.21)  6.65(1.47-30.01)  
College or above 2.71(0.73-10.01)  2.22(0.38-12.95)  3.56(0.75-16.76)  
30 
Marital status       
Married/living with 
partners 0.87(0.52-1.45) 0.7908 1.95(0.66-5.75) 0.2714 0.42(0.21-0.82) 0.0416 
Widow/divorced/separated 1.1(0.54-2.22)  2.62(0.8-8.56)  0.64(0.28-1.5)  
Never married 1[Reference]  1[Reference]  1[Reference]  
No. Alcohol/day       
No alcohol 1[Reference] 0.7144 1[Reference] 0.5197 1[Reference] 0.0727 
≥2 to <4/day 0.97(0.53-1.79)  1.45(0.83-2.5)  0.63(0.33-1.22)  
≥4 to <8/day 1.05(0.5-2.19)  1.22(0.49-3.01)  1.27(0.5-3.2)  
>8/day 1.59(0.59-4.31)  1.52(0.45-5.09)  1.6(0.53-4.81)  
Currently smoking       
Yes 1.88(1.29-2.74) 0.0009 3.7(1.83-7.49) 0.0003 0.96(0.48-1.92) 0.9088 
No 1[Reference]  1[Reference]  1[Reference]  
Age of sex debut      
<18 3.95(2.33-6.7) <.0001 3.65(1.56-8.55) 0.0028 3.68(1.63-8.31) 0.0017 
≥18 1[Reference]   1[Reference]   1[Reference]   
 
 
3.6 Factors Associated with Oral HPV Infection by Gender 
Males were 3 times more likely to be infected by HPV than females (adjusted OR, 3.41 
for any HPV infection, 3.26 for HRHPV, and 2.98 for LRHPV) (Table 6). Consistent with this, 
the weighted overall prevalence of any oral HPV was higher in males than that in females at all 
age groups. The prevalence of any oral HPV exhibited a trend to increase by age in men, but 
remained flat in women (Figure 5), 17.1% of men between 55-59 were HPV DNA positive, 
while the prevalence was only 1.1% in women at this age group (Figure 5). This data revealed a 
synergistic effect of gender and age on oral HPV prevalence. Consistent with this idea, gender 
and age showed interactions on the effect of any type HPV infection in a logistic model with 
these two variables (p<0.001). Notably, the oncogenic HPV16 was more than 7 times higher in 
males (1.73%) compared to that in females (0.23%). Without considering other factors, men 
were 7.6 times more likely to be infected by HPV16 than women (unadjusted OR: 7.6) (Figure 
6). To further understand the difference of risks between men and women, logistic models were 
constructed for men and women with several covariates including age, race, education, number 
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of alcohol consumed per day, current smoking, and age of sex debut. As shown in Table 7, Men 
and women exhibited profound differences in HPV infection risks across the characteristics. 
Gender showed interactions with age and race for any oral HPV infection of any type (p<0.05). 
For HRHPV, in addition to interaction between gender and age, gender and number of alcohol 
used per day were identified to have significant interaction (p<0.001), while gender and 
education showed marginal interaction (p=0.03) (Table 7). The risks (measured as adjusted OR) 
for any HPV type infection by age showed distinct patterns between male and female. The trend 
of risk increased by age for men but was flat for women (Figure 7). Consistent with prevalence 
data in Figure 5, the highest risk for men was at age of 55-59 (adjusted OR: 7.13 for men and 
0.22 for women). For HRHPV, the risk of infection in men were generally low during 18-44 
years of age and increased at age of 45-59. The highest risk was observed at age of 65-70 (Figure 
8).  Notably, women were more likely to have HRHPV infection when they were at age of 40 to 
44 (Adjusted OR=5.3) compared to other ages and men (Figure 8). Several characteristics, 
including education and use of cigarette, seemed to play a role in modifying the association 
between HPV infection and gender. Compared to men with education below high school, men 
with high school or college level education had higher risks for any HPV type infection (adjusted 
OR: 4.93 for high school and 4.13 for college and above; p=0.0396), as well as for HRHPV 
(adjusted OR: 5.58 for high school and 7.21 for college and above; p=0.0517) (Table 7 and 
Figure 9). By contrast, women’s risk for HPV infection was not associated with education (p 
value, 0.44 for any HPV and 0.31 for HRHPV). Smoking of cigarette seemed to increase risks in 
men (OR=4.77; p=0.011) significantly but moderately in women (OR=2.68; p=0.32) (Figure 10). 
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Figure 6 Weighted prevalence of oral HPV16 infection among U.S. 
adults by gender 
Figure 5 Weighted prevalence of oral HPV (any type) among U.S. 
populations by age and gender 
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Table 7 Adjusted Odds Ratio for HPV infection by gender in U.S. population aged 18-69 years 
  
Characteristic 
Overall HPV 
Adjusted OR (95%CI)  
P value for 
interaction 
with 
gender  
 HRHPV 
Adjusted OR (95%CI)  P value for interaction 
with gender Men Women Men Women 
Age       
18-24 1[Reference] 1[Reference] <.0001 1[Reference] 1[Reference] <.0001 
25-29 2.86(0.6-13.51) 0.25(0.05-1.22)  2.37(0.5-11.1) 0.26(0.02-2.58)  
30-34 1.37(0.38-4.92) 0.13(0.01-1.26)  0.39(0.07-2.13) 0.42(0.02-8.54)  
35-39 2.84(0.85-9.49) 0.69(0.15-3.12)  1.1(0.32-3.77) 0.81(0.03-18.03)  
40-44 2.78(0.76-10.08) 1.73(0.66-4.51)  0.74(0.14-3.97) 5.3(1.28-21.87)  
45-49 6.11(1.51-24.63) 0.14(0.02-1.05)  3.66(0.84-15.98) 0.53(0.02-9.97)  
50-54 4.78(2.22-10.28) 0.83(0.18-3.8)  3.72(1.43-9.65) 1.1(0.05-22.73)  
55-59 7.13(1.68-30.15) 0.22(0.03-1.53)  3.23(0.73-14.25) 0.54(0.04-6.89)  
60-64 3.9(0.89-17.14) 1.71(0.27-10.79)  1.65(0.45-6.04) 1.67(0.31-9.06)  
65-70 6.82(1.81-25.61) 0.29(0.06-1.37)  6.12(1.8-20.8) 0.36(0.03-4.2)  
p value <.0001 <.0001  <.0001 0.0007  
Race       
Mexican 
American 0.82(0.3-2.22) 1.18(0.14-9.69) 0.01 1.11(0.38-3.22) 1.39(0.13-14.5) 0.2676 
Other Hispanic 0.54(0.28-1.03) 0.68(0.21-2.22)  0.99(0.52-1.9) 0.98(0.21-4.56)  
NHW 1[Reference] 1[Reference]  1[Reference] 1[Reference]  
NHB 1.16(0.72-1.87) 1.29(0.51-3.27)  0.89(0.41-1.92) 0.21(0.02-2.15)  
NH Asian 0.35(0.1-1.23) 2.53(0.43-14.78)  0.5(0.05-4.31) 6.49(0.72-58.17)  
Other 0.74(0.14-3.71) 0.27(0.02-2.51)  0.72(0.13-3.88) 0.54(0.04-5.99)  
p value 0.0372 0.3239  0.966 0.2953  
Education       
Less than high 
school 1[Reference] 1[Reference] 0.1353 1[Reference] 1[Reference] 0.0309 
High school or 
equivalent 4.93(1.43-17.03) 1.18(0.23-6)  5.58(1.21-25.62) 0.82(0.13-4.99)  
College or above 4.13(1.18-14.41) 0.77(0.12-4.69)  7.21(1.46-35.5) 0.4(0.07-2.36)  
p value 0.0396 0.444  0.0517 0.3059  
No. Alcohol/day       
No alcohol 1[Reference] 1[Reference] 0.7238 1[Reference] 1[Reference] <.0001 
≥2 to <4/day 0.85(0.35-2.01) 1.26(0.57-2.76)  1.14(0.52-2.5) 5.98(1.46-24.33)  
≥4 to <8/day 0.83(0.32-2.17) 1.98(0.62-6.32)  0.61(0.21-1.75) 20.5(6.05-69.42)  
>8/day 1.42(0.36-5.53) 2.28(0.33-15.64)  1.24(0.34-4.46) 8.11(2.44-26.92)  
p value 0.762 0.7174  0.6573 <.0001  
Currently 
smoking       
Yes 2.09(1.24-3.53) 1.68(0.76-3.67) 0.5362 4.77(1.87-12.16) 2.68(0.38-18.61) 0.6522 
No 1[Reference] 1[Reference]  1[Reference] 1[Reference]  
p value 0.0055 0.1943  0.0011 0.3181  
Age of sex 
debut       
<18 3.57(1.75-7.3) 7.02(1.86-26.46) 0.2296 3.5(1.23-9.97) 5.71(0.86-37.7) 0.1736 
≥18 1[Reference] 1[Reference]  1[Reference] 1[Reference]  
p value 0.0005 0.004   0.0185 0.0701   
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Figure 7 Adjusted Odds Ratio for oral HPV (any type) infection 
among U.S. adults by age and gender 
Figure 8 Adjusted Odds Ratio for oral HRHPV infection among 
U.S. adults by age and gender 
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Figure 9 Adjusted Odds Ratio for oral HPV (any type) infection 
among U.S. population aged 18-69 years by education and gender  
Figure 10 Adjusted Odds Ratio for oral HPV infection among 
U.S. population aged 18-69 years by tobacco use and gender  
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Despite the lower oral HPV prevalence in women compared in men, some group of 
women appeared to have be at high risk of being infected, particularly for HRHPV.  As shown in 
Table 7 and Figure 11, women who drank had much higher risks for HPV infection than men. 
Strikingly, women who had more than 2 alcohols per day were much more likely to be infected 
by HRHPV than those who did not drink (Adjusted OR range: 5.98-20.5). By contrast, drinking 
alcohols appeared to have little effects in men (Figure 11).  Interestingly, among race groups, 
Asian males had the lowest risk for HPV infection (adjusted OR, 0.35 for any HPV and 0.5 for 
HRHPV), but Asian female were highly vulnerable to HPV infection, particularly to HRHPV 
(adjusted OR, 6.49) (Table 7 and Figure 12). Black women had the lowest risk for HRHPV 
(adjusted OR, 0.21). Age of sex debut was another risk factors for HPV infection. Both men and 
women who started sex younger than 18 years old were more likely to have HPV infection than 
those who started sex after 18 years old (Table 7). Women seemed to be more vulnerable to HPV 
infection when they started sex before 18 years of age (adjusted OR: 7.02 in women vs 3.57 in 
men for any HPV, 5.71 in women vs 3.51 in men for HRHPV infection) (Figure 13).  
Race and number of life time opposite sex partners showed significant interactions in the 
pair wise test. The effect of the number of life time opposite sex partners on oral HPV prevalence 
differed by race. Figure 14 showed the weighted prevalence of any HPV types over life time sex 
partners by race.  The HPV prevalence increased in all race groups as the number of sex partners 
increased from 2-5 to more than 10. It increased more sharply in Non-Hispanic White and Black 
than in Mexican Americans and Asians. For people with less than 2 partners, Mexican and Black 
had relative high prevalence (Figure 14). 
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Figure 11 Adjusted Odds Ratio for HRHPV infection among U.S. 
population aged 18-69 years by gender and alcohol use 
Figure 12 Adjusted Odds Ratio for HRHPV infection among U.S. 
population aged 18-69 years by gender and race 
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Figure 13 Association of gender and age of sex debut with oral HPV infection among U.S. 
population aged 18-69 years 
 
 
 
 
 
 
Figure 14 Weighted prevalence of oral HPV (any type) infection among U.S. adults by race and 
number of lifetime opposite sex partners 
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4 DISCUSSION 
In this study, we used nationally representative sample of U.S. population collected 
through NHANES to study oral HPV infection. The prevalence oral HPV among U.S. population 
aged 18-69 years was estimated as 7.18%, 4.5% and 3.5% for any HPV types, HRHPV, and 
LRHPV, respectively. These results were comparable with previously reported oral HPV 
prevalence of 6.9%, 3.7% and 3.1% for any types, HRHPV and LRHPV, respectively [13]. The 
oral HPV prevalence was substantially lower than that of genital HPV infection in men or 
women [20, 21, 50]. Thirty-six HPV types were detected in the samples. The most prevalent oral 
HPV type was HPV16 (0.97%). HPV infection was associated with sexual history and several 
demographic characteristics, including age, gender, and race.  Alcohol and tobacco use were 
identified as potential risk modifiers for HPV infection in men and women. 
4.1 Overall Prevalence of Oral HPV Infection 
Prevalence of any HPV types was the lowest among 18-24 years old people (5.0%), 
increased to a peak (9.4%) among people at age of 50-54, and decreased to 6.3% in 65-70 years 
of age. The prevalence of HRHPV and LRHPV over age each followed a bimodal pattern with 
peaks at 25-29 years and 50-54 years for HRHPV, and with peaks at 40-44 and 60-64 for 
LRHPV. This pattern for HRHPV infection was similar with that in a previous report [13]. 
However, the age when prevalence peaks occurred for HRHPV and LRHPV were different from 
that of previous report in which the bimodal pattern was observed with peaks at 30-34 and 60-64 
years of age for both HRHPV and LRHPV [13]. Similarly, prevalence of genital HPV in men 
follow a bimodal pattern with peaks at 28-32 years and 58-59 years [21]. The reason for these 
age-related changes in prevalence are not clear, but are likely resulting from the difference of 
samples sets, or related to factors including clearance of virus over time, alternative transmission 
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route for oral HPV, changes of incidence caused by sexual behavior changes, or changes in 
immune systems [20]. 
4.2 Prevalence of Oral HPV Infection Varies by Characteristics 
Oral HPV prevalence differed across categories of demographic and behavioral 
characteristics including gender, country of birth, race, education, marital status, as well as 
alcohol and tobacco use.  This is similar with previous observation for both oral and genital HPV 
infection [13, 20, 21]. An analysis of the effects of oral health on HPV infection, including 
decayed teeth, gum disease and oral hygiene, was not possible because of low number of 
participants who answered “No” to these questions. Prevalence of oral HPV infection (any HPV 
type, HRHPV, and LRHPV) was higher in individuals with sexual experience and increased with 
number of life time sex partners. Prevalence of oral HPV among people who started sex before 
18 years of age was 2-3 time higher than those who started sex after 18 years old. People who 
had multiple same sex partners had the highest prevalence (32.7%). Oral HPV prevalence were 
higher among people who had new partners in past 12 months. These data suggest that HPV 
infection is strongly associated with sexual behavior, supporting the opinion that sexual contact 
was the major route for oral HPV transmission [13]. It should be pointed out that assessment of 
associations between any single sexual behavior and HPV infection is difficult due to the high 
collinearity among sexual behaviors [13]. Of note, sexual history and sexually transmitted 
disease status were self-reported and there were considerable number of nonresponses, which 
may not be accurate due to misclassification and the sensitivity of the topics [20, 21]. 
4.3 Factors Associated with Oral HPV Infection 
Univariate analysis identified 16 characteristics that potentially contribute to oral HPV 
infection (p<0.05). 9 significant characteristics were selected for multivariable regression 
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analysis. Some of the behavioral characteristics, including sexual behavior as well as alcohol and 
tobacco use, had collinearity and were analyzed separately.  This analysis revealed four risk 
factors that were independently associated with oral HPV infection of any type including age, 
gender whether or not smoke at time of interview, and age of sex debut. These results were 
consistent with previous reports [13]. Furthermore, we identified country of birth, in addition to 
the four factors for any types, to be associated with HRHPV. We found that LRHPV infection 
was associated with six factors including age, gender, race, education, marital status, and age of 
sex debut. Surprisingly, whether or not smoke at time of interview was not associated with 
LRHPV infection (p=0.9).  All the 3 HPV categories (any type, HRHPV and LRHPV) included 
3 independently associated factors, age, gender, and age of sex debut, which were reported as 
risk factors for genital HPV infection as well [20, 21]. The association of sexual behavior with 
HPV infection was consistent with previous report that oral HPV was predominately sexually 
transmitted [13, 38]. In the dataset used in this study, people age 65-70 years had the highest risk 
for any types and HRHPV, possibly due to changes in hosts’ immune system as they aged, 
though the reason was unknown. People aged 30-34 years had lowest risk for HRHPV, which 
followed the first HRHPV prevalence peak at 25-29. This may reflect the active immune 
responses for virus clearance after a wave of HPV infection. 
4.4 Differences of Oral HPV infection in Males and Females 
It has been reported that HPV prevalence is different between male and female [13, 38]. 
Our data provided additional evidence for this point. We found that male and female differed 
profoundly regarding to the sensitivity of oral HPV infection in response to risk factors. Oral 
HPV prevalence was higher in men than that in women at all age stages. The prevalence of oral 
HPV tended to increase by age in men. The highest prevalence (17.1%) of oral HPV was found 
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in men aged 55-59 years. One explanation for this observation was decreased immune response 
to natural infection in men as they aged [51, 52].  We identified an interaction between gender 
and age on infection of any HPV type. HPV prevalence (any type) in men at age of 55-59 years 
were 17 times higher than women at the same age (adjusted OR: 7 times higher). To further 
assess the clinical consequences of HPV infection, we evaluated the risk factors for HRHPV. In 
addition to interactions between age and gender, number of alcohol consumed per day interacted 
to gender to exert effect on HRHPV infection. Men had nearly 4 times higher risk for HRHPV 
infection at their age of 45-59, compared to women in the same age. In addition, the prevalence 
of the oncogenic HPV16 was higher in males than females. These data may provide some 
explanations for higher prevalence of OPCs observed in men [34, 53]. Age of sex debut of 
younger than 18 can increase risk for oral HPV infection more than 3 times. Other factors 
including education and whether or not smoke seemed to be risk modifiers for HPV infection in 
men.  
We found that certain group of women were at particularly high risk for HPV infection. 
First, women at age of 40-44 were 5 times more likely to have HRHPV infection than those of 
other ages. Second, women who drank more than 2 alcohols per day were at much higher risk (5-
20 times) than those who did not drank and men. Third, Asian women seemed to be more 
vulnerable to HRHPV infection (adjusted OR, 6.49) than men and women of any other ethnic 
groups. Finally, women were twice more likely to be infected by HPV than men if their age of 
sex debut were younger than 18 and had 5 to 7 times more risk compared to women who started 
sex after 18 years old. These data identified subgroups of women who were at higher risk for 
HPV infections at certain conditions and would be helpful for development of tailored 
43 
prevention programs. An evaluation of HPV16 by subgroups was restricted by the low number 
of HPV16 positive subjects in the dataset. 
4.5 Limitations 
 This study has several limitations. First, the prevalence of HPV infection could be under-
estimated. This study relied on HPV DNA positivity detected by Roche LA, which only covered 
37 types out of more than 200 known HPV types. Those types that were not on LA test were not 
reported even if they were present in the samples. New technologies such as Next Generation 
Sequencing (NGS) allow for simultaneously testing for all known HPV types [54]. The 
implementation of NGS-based method into survey data would provide more accurate estimation 
for HPV prevalence. Second, the data are cross-sectional and only provide a snapshot of HPV 
infection. Therefore, the study cannot distinguish between incidences from prevalence. We 
cannot calculate accumulative infections. This could result in incomplete pictures for HPV 
infection because HPV infection is dynamic and could be transient as a result of immune system 
clearance. Therefore, the prevalence estimate does not reflect the lifetime infection of HPV. 
Serologic testing that detects antibodies against HPV specific proteins provides better estimate 
for cumulative infection [55]. Third, self-reported information on characteristics are incomplete 
and might be inaccurate due to misclassifications or involving sensitive topics that participants 
are not willing to answer. Finally, estimates for prevalence of HRHPV and LRHPV are subjected 
to changes according to HPV classification. HPV risk classification is evolving as more data 
available on the oncogenicity of a HPV type and natural history of infection [20, 56]. It should 
be pointed out that some of the types classified as HRHPV in this study only had limited 
evidence to cause cancer [56]. The classification used in this study was selected to enable 
comparison with previous studies.   
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5 CONCLUSIONS 
This study provided a national representative estimate for prevalence of oral HPV 
infection among population aged 18-69 years in the United States using the most update data in 
NHANES. The overall prevalence of any oral HPV types infection was estimated as 7.18% and 
the oncogenic high-risk HPV prevalence was 4.5%. The distribution of oral HPV infection 
varied by demographic and behavioral characteristics. Oral HPV infection was highly associated 
with sexual history. Age, gender, and sexual behavior were common risk factors for HPV 
infection. Prevalence of oral HPV infection were significantly higher in males than that in 
females. Our data suggested that factors including use of alcohol and tobacco were risk modifiers 
for HPV infection in males. We identified several subgroups of women who were at high risk for 
oral HPV infection including women aged 40-44 years, women who drank more than 2 alcohols 
daily, women who started sex before 18 years old, and women of Asian group. In conclusion, our 
study provided the most update estimate for oral HPV infection at population level and identified 
factors conferring significant risks for oral HPV infection. Our data provided additional evidence 
that sexual contact was a major route for oral HPV transmission. The finding in this study has 
important implications on oral HPV surveillance and epidemiological study. 
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